Study protocol for a multi-centre stepped-wedge cluster randomised trial to explore the

usability and outcomes among young people living with HIV in Kiambu and Kirinyaga

counties of Kenya, using an online health portal.

Eric Nturibi[1][*][¶], Jared Mecha[1][¶], Elizabeth Kubo[1][¶], Albert Orwa[1][¶], Florence Kaara[1][&], Faith

Musau[1][&], Christine Wamuyu[1][&], Justus Kilonzi[2][&], Randeep Gill[3][¶], Sanne Roels[3][&]

Correspondence to Eric Nturibi, Email: ericmugambi@gmail.com, Tel: +254-722758767

Affiliations

1. Department of Clinical Medicine and Therapeutics, University of Nairobi School of

Medicine, Nairobi, Kenya

2. Savannah Informatics LTD, Kenya

3. Janssen Pharmaceutica NV

*Corresponding author

Email: ericmugambi@gmail.com

¶These authors contributed equally to the work

&These authors also contributed equally to the work

Short title: Online health portal use in youth with HIV: a stepped wedge cluster RCT

ABSTRACT

Introduction: While the incidence of HIV declines in most age groups globally, it continues to

rise among adolescents and young adults who also experience a higher rate of HIV-related

deaths. These tech-savvy individuals might benefit from an online patient portal aimed at

increasing awareness, building skills, and promoting patient activation – the willingness and

capacity to independently manage their health. However, the impact of such portals on young

HIV patients in Kenya remains uncertain. **Methods and analysis:** HIV patients aged 15-24 with

smartphone access will participate in a 12-month stepped wedge cluster randomized trial. The

main focus will be the portal's effect on patient activation, with secondary outcomes being self-

reported adherence, viral suppression, and social involvement. The study also aims to understand

the portal's development, implementation, functionality, usability, and cost. From 47

antiretroviral therapy (ART) sites with electronic medical recording systems, 16 clusters of 30

participants each will be formed. These clusters, over 12 months, will be randomized into 3

intervention sequences every 3 months. Baseline measurements, covering patient activation,

adherence, viral load, and social engagement, will be recorded over two weeks, with subsequent

checks at 3, 6, and 12 months. Data will be analyzed using generalised linear mixed models.

Ethics and dissemination: The protocol has received approval from the AMREF Health Africa

Ethics & Scientific Review Committee (ESRC) and local governments. Findings will be shared

through stakeholder forums, conferences, publications, and media.

Author Summary

What is the issue? HIV infections among teenagers and young adults are increasing, particularly

in Kenya. Given their technological inclination, an online portal might help them manage their

health. The effectiveness of this approach remains uncertain.

What are our actions? We are running a year-long study in Kenya with HIV-positive

individuals aged 15 to 24 who have smartphones. The goal is to see if the portal aids their health

management. We're assessing health readiness, medication adherence, HIV control, and social

connection. The study involves groups from 47 HIV treatment centers, with new groups

engaging with the portal every three months.

What are our assessment methods?

We will use statistical methods to gauge the portal's impact on health management.

Is the study approved?

Yes. It has endorsements from AMREF Health Africa and local governments. Results will be

shared with the community, at conferences, in scientific journals, and in the media.

Introduction

Of the 37.7 million persons living with HIV (PLHIV) worldwide in 2020, 25.3 million were resident in sub-Saharan Africa (SSA), where 460,000 of the 680,000 global AIDS related deaths (ARDS) also occurred (UNAIDS, 2021). In 2020, 400,000 adolescents and young persons (AYP) were newly infected with HIV, of whom 150,000 were aged 10 to 19[1]. Globally, whereas new HIV infections are declining for other age groups, they are increasing in the adolescent age group (10-19yrs), who also contribute disproportionately to ARDs[2]. In 2020, there were an estimated 1.4 million PLHIV in Kenya including 160,000 young persons (ages 15-24). Of the estimated 33,000 new infections, 35% occurred in young persons (ages 15-24)[3]. With 59.24 million connections as at January 2021, Kenya had a mobile penetration of 108.9% and an internet penetration of 40% (21.75 million), including 11 million social media users[4]. According to a report by the United Nations, young people in low and middle income countries (LMICs) are nearly three times more likely to be using the internet than the general public[5]. A recent review of digital health solutions (DHS) for engaging PLHIV decried the lack of published interventions targeting the more than 4 million young people aged 15-24 living with HIV globally, despite their identification as a "critical group experiencing multiple barriers to engagement in care."[6]. Patient health portals are therefore particularly attractive in this vulnerable population who are likely to welcome digital health solutions more readily than other age groups.

The functionalities proposed in the digital health platform, myCareHub™, have been carefully designed to incorporate mechanisms identified as critical for outcome achievement (fig 1) [7] and are based on the COM-B framework (fig 2) that links behaviour to capability, opportunity, and motivation [8].

 Figure 1: Mechanisms of patient activation (adapted from Otte-Trojel, de Bont (7))

Figure 2: COM-B theoretical framework for behaviour change

The design was heavily influenced by the views and preferences of the intended users

(unpublished data) with inputs from an experienced team of AYP resource persons.

myCareHub™ will be accessible on internet enabled mobile phones through a dedicated

password to ensure security and confidentiality of data. It is designed to offer a wide array of

services to healthcare providers (HCPs) and patients (fig 3).

Figure 3: Diagrammatic representation of myCareHub™ and functions available to use.

This study seeks to establish whether an online patient health portal, myCareHub™ improves

AYP activation and consequent engagement in HIV care and treatment. Further, in line with

World Health Organization (WHO) guidelines for mobile health evidence reporting and

assessment (mERA), the study will explore quality, fidelity, and coverage of the platform, as

well as key program indicators (fig 4)(9); features that are often overlooked in published studies.

Figure 4: Intervention life cycle of a digital intervention

The findings of this study will inform HIV programming for young persons and other vulnerable
populations, shift health policy on digital health solutions and contribute substantially to the
elimination of AIDS as a global threat by 2030.

Methods and Analysis

Setting

The University of Nairobi – Central Kenya Response: Integration, Strengthening and

Sustainability Plus (CRISS Plus) project is a 5-year PEPFAR-funded HIV prevention, care &

treatment project in partnership with Kiambu & Kirinyaga county governments. The project

currently supports HIV related activities at 78 public facilities. Forty-seven (47) facilities have an

electronic medical records (EMR) system. The 47 EMR sites will be clustered based on

geographical proximity loosely coinciding with sub county territorial assignment of the facilities

and covering 15 out of the 17 supported sub-counties. The largest treatment site will constitute

the 16th cluster on account of the large number of adolescent and young people enrolled in its

antiretroviral treatment (ART) program.

At study inception, the program provided ART for 38,079 PLHIV, of whom 3,459 (9%) were

AYP. The target population for the study will be AYP (ages 15-24 years) enrolled in supported

clinics. Eighty-nine per cent (89%) of the target population are enrolled in the 47 EMR sites.

Study design

We plan to conduct a multicentre stepped wedge cluster randomised trial to assess whether a

bespoke patient health portal, myCareHub™, can improve patient activation and clinical

outcomes among consenting individuals aged 15 to 24 living with HIV and attending the ART

clinic at one of 47 EMR-enabled treatment centres (table 1). Caregiver consent will be obtained

for participants under the age of 18.

Table 1: PICOT Framework	
Population	Adolescents and young persons (15-24 years old) attending an EMR-enabled Anti-Retroviral Treatment (ART) site and with ready access to a smartphone
Intervention	Making a patient health portal with several functionalities available
Comparator	Standard of care patient engagement strategies
Outcome	Patient activation as the primary outcome. Secondary outcomes: viral load, social engagement measures, adherence, and portal use features
Time	15 months total, the first three being control, with 3-month intervals between sequences, and measurements taken over a 2-week period. Once all clusters cross over from control to intervention, an observation period of 6 months will follow.

112   In total, a minimum sample of 480 adolescents and young persons will be recruited into 16

113   clusters using a stepwise design (table 2) with intervals of three months between successive

114   steps.

	TO:	2wks	T1: Mo 1 – 3	2wks	T2: Mo 4 – 6	2wks	T3: Mo 7 - 9	2wks	T4: Mo 10-12	2wks
CLUSTERS 11 - 16	CONTROL		CONTROL		CONTROL		INTERVENTION		INTERVENTION	
CLUSTERS 6-10	CONTROL		CONTROL		INTERVENTION		INTERVENTION		INTERVENTION	
CLUSTERS 1-5	CONTROL		INTERVENTION		INTERVENTION		INTERVENTION		INTERVENTION	
Time	TO:	2wks	T1: Mo 1 – 3	2wks	T2: Mo 4 – 6	2wks	T3: Mo 7 - 9	2wks	T4: Mo 10-12	2wks

Survey details (in 2wks columns):

- **T0.:** Baseline survey: Demographics, Clinical enquiry (medical history), Baseline PAM, Adherence, VLS, social engagement scores on SSQ6: cluster level retention. Cluster VLS
- **T1 survey**: 3 Mo PAM, Adherence, VLS, portal measures: TB ICF, PDQ-9, CRAFFT, SGBV screening, Contraceptive use intention; feedback on portal: cluster level retention, Cluster VLS
- **T2 survey**: 3, 6 Mo PAM, adherence, VLS, retention, portal measures: TB ICF, PDQ-9, CRAFFT, SGBV screening, Contraceptive use intention; feedback on portal: cluster level retention, Cluster VLS
- **T3 survey**: 3, 6, 9 Mo PAM, adherence, VLS, retention, portal measures: TB ICF, PDQ-9, CRAFFT, SGBV screening, Contraceptive use intention; feedback on portal: cluster level retention, Cluster VLS
- **T4 survey:** 6,9 & 12 Mo PAM, adherence, VLS, MAUQ, acceptability score, portal measures: TB ICF, PDQ-9, CRAFFT, SGBV screening, Contraceptive use intention; feedback on portal: cluster level retention, Cluster VLS

*PAM – Patient activation measure, VLS – Viral load suppression, SSQ6- Social Support Questionnaire, short form, MAUQ – mHealth App Usability Questionnaire: TB ICF – Tuberculosis intensified case finding, SGBV – sexual and gender-based violence, CRAFFT – Car, relax, alone, forget, friends, trouble

118   Stratification of clusters will be conducted based on size, sex/gender mix and viral load

119   suppression (table 3) to come up with comparable blocks of clusters prior to randomisation (table

120   4).

121   *Table 3: Sub-counties by key attributes*

Sub-county	Number of AYPs	Size Strata	*VLS 15-19	VLS 20-24	Cohort retention	Males (%)
Thika town	632	Large	80%	90%	89%	41%
Ruiru	330		84%	89%	68%	25%
Kiambu town	205	Medium	86%	89%	100%	32%
K Central	176		86%	90%	84%	55%
Gatundu South	166		61%	90%	50%	40%
Juja	146		91%	82%	67%	35%
Kiambaa	123		87%	91%	100%	27%
Kirinyaga South	116		91%	87%	88%	53%
Githunguri	113		85%	89%	100%	27%
Kabete	110		94%	94%	100%	23%
Gatundu North	107		92%	89%	100%	40%
Limuru	103		90%	100%	100%	35%
Kirinyaga West	88	Small	81%	92%	74%	37%
Kikuyu	73		100%	90%	100%	16%
Kirinyaga East	58		100%	86%	87%	57%
Lari	51		100%	91%	100%	23%
Kirinyaga North	50		60%	68%	88%	48%
*VLS – viral load suppression						

Clusters within each comparable block (stratum) will be randomly assigned to one of the three

sequences for time of crossover from control to intervention using a computer-generated list of

random numbers. Clusters will receive the intervention in groups of five and six. There will be a

total of 3 intervention sequences – the third extending 6 months. Each cluster will begin in the

control period and eventually receive the intervention, with the order of crossover being

randomly determined. An interval of two weeks between intervention sequences will be

incorporated to allow for measurements to be taken and the intervention to be introduced to new

clusters.

Table 4: Randomization of clusters into sequences

S/No.	Cluster	15-19 yrs.	20-24 yrs.	Total AYP	Strata Size	Random number	Seq	No. of AYP (n=480)
1	Juja	48	98	146	Medium	0.91499	1	186
2	Kiambaa	30	80	110	Medium	0.842108	1	
3	Kirinyaga Central	76	83	159	Medium	0.637954	1	
4	Kabete	19	75	94	Small	0.969301	1	
5	Kirinyaga South	27	48	75	Small	0.832712	1	
6	Ruiru	77	253	330	Large	0.725233	1	
7	Gatundu South	75	91	166	Medium	0.555849	2	170
8	Gatundu North	52	55	107	Medium	0.546696	2	
9	Limuru	41	62	103	Medium	0.541296	2	
10	Lari	12	23	35	Small	0.701539	2	
11	Kirinyaga East	29	26	55	Small	0.567749	2	
12	Thika Level 5	172	196	368	Large	0.226127	2	
13	Githunguri	45	56	101	Medium	0.458081	3	124
14	Thika Town	102	135	237	Medium	0.379402	3	
15	Kiambu Township	87	112	199	Medium	0.062999	3	
16	Kirinyaga West	29	42	71	Small	0.514886	3	

Justification of stepped wedge design

The stepped wedge design was chosen as individual randomization into control and the patient

portal within a facility would inevitably lead to contamination as the control group would

inadvertently be exposed to the intervention. The staggered approach to implementation also

allows for enhancements to the portal based on lessons learned from preceding clusters.

Study population

In our study, the intervention will be targeted at clusters, where a cluster is defined as a group of

EMR-capable facilities in geographical proximity. Outcome parameters will be determined at

patient level. Two key strategies will be employed to recruit participants into the study. A line

listing of all AYP in the participating EMR sites will be done from the central EMR database and

random number sequences used to select eligible participants per facility with allowance made

for refusals. Selected participants will then be invited for an open day activity during which

recruitment will be done after obtaining informed consent. Weekly appointment diaries will also

be used to line list AYP due for their clinic visit in the coming week with a random number

sequence generated and applied to select eligible participants. These strategies will be

undertaken repeatedly until the required sample size is obtained. Measurements will be taken on

the same cohort and by the same observer at the end of each successive step when a cluster

moves from control to the active intervention (table 2).

Intervention

myCareHub™ will be available on google play-store and iOS app-store. The portal has been

developed by the study team with significant input from end users and is designed to offer

several functionalities critical for catalysing the behaviour change process as per the COM-B

framework (figs 2&3). The portal will comprise two mobile based applications: a patient portal

and a health care provider (HCP) portal. Features available to patients will include e-learning

resources in text, audio, videos and other media, focussing on HIV treatment literacy, disclosure

support, adherence support, sexual and reproductive health (SRH) and coping skills; online

communities for peer-to-peer networking and learning; an online patient diary to support self-

monitoring by enabling patients to view their medical data from the facility based EMR and to

record and share their experiences with HCPs; online based web forms and survey tools to

capture patient reported outcomes which will trigger a service request on the HCP portal so that

care can be personalised and offered without delay; in app and short message service (sms)

notifications for appointments and other reminders; and a mechanism for appointment

rescheduling (to be developed in the second phase). The HCP portal will enable providers to

track and monitor patient treatment, adherence, and symptoms, and to provide personalised care

based on response data from the patient diary. As the apps are linked and synchronised with the

facility EMR, HCPs can capture and access longitudinal patient level visit data and other medical

information such as laboratory investigation reports. On a quarterly basis, open forums will be

conducted with portal users - HCPs and patients, to ensure they can access and use all the

available features and to capture qualitative end-user insights.

Outcome parameters

Outcome parameters will be measured in individuals at pre-specified time points, baseline, every

3 months, and end-line (table 5), using digitised case report forms.

 Table 5: Outcome variables

Variable	Definition	Units	Instrument/source	Measurement level	Measurement period	Comparison Groups	Analysis
PAM	Patient activation measure	100-point scale	PAM-13	Individual	Baseline, 3Mo, 6 Mo, 9Mo	Intervention vs. control	Mean change in PAM in the Intervention vs. control
Self-reported Medication adherence	Estimate of adherence on 0-100% scale	Proportion	Visual analogue scale and adherence questionnaire	Individual	Baseline, 3 Mo, 6 Mo, 9 Mo	Intervention vs. control	% Adherence Int. vs. control
VL suppression (VLS)	Dichotomous, suppressed (below low limit of detection, LDL) vs. not suppressed (above LDL)	Suppressed/ not suppressed	EMR record	Individual	Baseline, 3 Mo, 6 Mo, 9 Mo	Intervention vs. control	% VLS intervention vs. control
Cluster retention	Active in care at the end of reporting period/active at the beginning of the period*100	Proportion	Routine program data	Cluster	Baseline, 3Mo, 6Mo, 9Mo	Intervention vs. control	% Retention intervention vs. control
Cluster VLS	Percent viral load suppression	Proportion	Routine program data	Cluster	Baseline, 3Mo, 6Mo, 9Mo	Intervention vs. control	% VLS intervention vs. control

	within cluster						
Mobile health application Usability Score	Numerical score: More being more usable	Mean score	MAUQ mHealth App Usability Questionnaire (MAUQ) for Interactive mHealth Apps Used by Patients & HCPs	Individual	End-line	Intervention	Mean score by baseline characteristics
Acceptability score	Mixed tool: Likert-like Scale and text	sub-section scores	Custom acceptability tool	Individual	End-line	Intervention	Mean scores by baseline characteristics
TB case finding	Screening 4 questions each score 0 or 1. Total score 4	0-4	**Portal** TB case finding tool Paper-based TB case finding tool	Individual	continuous	Intervention vs. program	1. Proportion of participants who reported 3 out of 4 symptoms on the portal. and % of these who reported to the facility for further evaluation and % of these with confirmed TB 2. % of total TB cases that were

							identified through the portal [Total # of TB cases identified through the portal during study duration/ Total # of TB cases identified overall (portal + standard of care) during the same duration] *100
Mental health screening for depression	9 questions each scored 0-3 for total possible score of 27	0-27	**Portal** incorporated PHQ-9	Individual	continuous	intervention	Proportion participants with mild, moderate, severe depression; and % of these referred for timely further assessment % Total depression cases that

							were identified through portal - [Total # of depression cases identified through the portal during study duration/ Total # of depression cases identified overall (portal + standard of care) during the same duration] *100
Contraceptive use intention screening	4 questions on contraceptive use desire and eligibility	LMP Y/N to pregnancy Y/N to using or desiring contraceptives	**Portal incorporated** contraceptive use intention screening tool	Individual	continuous	intervention	Proportion users eligible for contraceptives and successfully referred % All contraceptive uptake requested from portal -

							[Total # of contraceptive uptake requests from portal during study duration/ Total # of contraceptive uptake requests overall (portal + standard of care) during the same duration] *100
Sexual and Gender Based Violence (SGBV) screening	4 questions screening for emotional. Physical, sexual, and intimate partner violence; each has either Y/N answer	Y/N	**Portal** incorporated SGBV screening tool	Individual	continuous	intervention	% Survivors successfully identified & referred % Total SGBV cases reported through portal - [Total # of SGBV cases reported through the portal during the study duration/

							Total # of SGBV cases reported overall;(portal + standard of care) during the same duration] *100
Alcohol and substance use disorder screening	Six questions, 2 or more affirmative answers indicating alcohol or drug use problem	Y/N	**Portal** incorporated CRAFFT tool	Individual	continuous	intervention	%Youth with disorder successfully identified & referred

% Of total identified originating from portal - [Total # of youth identified with the disorder through the portal during the study duration/Total # of youth identified with the disorder overall (portal |

							+ standard of care) during the same duration] *100
Social engagement	Six questions on social supporters	Names of supporters and ratings of support	SSQ-6 at baseline Online communities' engagement metrics	Individual	Baseline, continuous	n/a	Engagement in communities' vs baseline engagement

The primary outcome will be change in patient activation measure (PAM) at 6 and 9 months.

Secondary outcomes will include self-reported adherence (months 3,6 &9) and latest viral load.

Portal-based measures

Portal-based measures will include portal functionality, quality, fidelity, and an estimate of total

cost in setting up the portal. Four key elements of the patient diary – screening for Tuberculosis

(TB) and sexual and gender-based violence (SGBV), contraceptive needs assessment and

screening for alcohol and substance use disorders will be monitored, and the time taken for HCPs

to resolve service requests recorded and compared to usual non-portal based clinical practice. An

analytical dashboard will be developed to provide real time updates on portal engagement

metrics.

Evaluating Usability

Participation in online communities will be tracked and compared with baseline social

engagement score (SES).

During the study, focus group discussions (FGDs) will be used to elicit insights into the client

experience of the portal that will go towards future enhancements.

A mobile health app usability survey (MAUQ - patient and health care provider) and an

acceptability survey will be administered at the end of the intervention period.

Statistical methods

Baseline participant characteristics i.e., sociodemographic (age, sex, occupation) and clinical

information (duration on ART, presence of treatment buddy and last viral load) will be described

by cluster.

The primary outcome will be analysed as mean PAM/ change in PAM score between

intervention and control groups at 6 and 9 months by age category (15-19 vs. 20-24), sex (male

vs. female) and duration on ART (<12 months and >12 months). PAM total scores of 0 and 100

will be considered as missing data and PAM changes will be analysed over time and across PAM

levels as per the developer's recommendations.

Statistical analysis of the primary and secondary endpoints will be conducted in either R or SAS

using generalised linear mixed models which allow for incorporation of correlations due to

repeated measures, cluster effects and potential time effects. Sensitivity analyses, including use

of causal inference methods, will be conducted to assess the effect of differential patient and/or

cluster characteristics over time and/or attrition on the comparison between intervention periods.

Thematic analysis will be conducted on qualitative insights from FGDs, and the operational and

other costs related to running the portal tracked to facilitate cost analysis.

Sample size

The primary outcome will be a change in patient activation measure (PAM) (Hibbard JH, et al,

2004). Lin and co-authors found an average effect size of 0.33 in a meta-analysis on studies

involving patients with chronic disease reporting change in PAM (Lin et al., 2020). Also, a

difference of 4 points on the PAM scale is considered clinically important and Marshal et al were

able to demonstrate that a 5-point difference was significantly associated with higher odds of

CD4 count>200, retention, and viral load suppression (J. H. Hibbard & Tusler, 2007; Rebecca

Marshall et al., 2013). Following the definitions as outlined in Hooper et al., 2006, assuming an

intra- cluster correlation of 0.02 and individual autocorrelation of 0.8, and only low "time by

cluster" effects impacting the PAM scores, the study will require a minimum sample size of 27

per cluster to demonstrate a change of 5 point (green lines in figure 5) in the activation score

between the two groups, assuming the same standard deviation as in Marshall, Beach (10) with a

power of at least 90% at an alpha of 0.05% (11).

Figure 5: Sample size estimation for stepped wedge design

It is worth noting that the power to demonstrate a difference will be affected substantially by the

cluster by time effect. Hemming et al. provided minimal guidance – but did mention a range on

that correlation between 0.3 (large effect) to 0.9 (small effect). They strongly suggest a

sensitivity analysis on these assumptions, which is provided in Figure 5. Focusing on the green

lines, in the presence of high intra-participant variability but small time by cluster effects,

approximately 90% power can be attained with 22 participants per cluster. However, if the time

by cluster effect is stronger, power to demonstrate 5 points change drops to 80%. A 10% increase

in sample size will be added to account for non-participation, requiring a total of 30 participants

per cluster. Based on the above assumptions, the total minimum sample size is therefore

estimated at 30*16=480. The number of participants lost to follow-up will be monitored

throughout the study, and mitigation strategies implemented to accommodate any unforeseen

impact by additional recruitment of patients. To compute the sample size for each site, a

weighting based on the total AYP will be used. The following formula will be used to obtain a

sample for each of the study sites.

$$n_i = \frac{N_i}{N}$$

where, n_i = Sample size for site i, N_i = total AYP in site i and N = total AYP in all the study

sites

Ethical approval

The AMREF Health Africa Ethics & Scientific Review Committee (ESRC) and the respective

County Health Departments have both sanctioned this protocol. Every participant involved

provided their informed and written consent. For participants aged between 15 to 17 years, the

study investigators were granted a waiver for parental consent by the Ethics and Scientific

Review Committee (ESRC). This decision was based on several considerations: to avoid

unintentional revelation of the HIV status, to enhance the participation rate, and to mitigate

selection bias, especially since the study entailed minimal risk to its participants. Furthermore,

the National Commission for Science, Technology, and Innovation (NACOSTI) has provided a

research license permitting the execution of the study. Additionally, this trial has been

catalogued in the Pan African Clinical Trial Registry at www.pactr.org with the distinctive ID:

PACTR202303729957231.

Dissemination of results

Research results will be disseminated via stakeholder forums, scientific conferences, research

publications and the media.

Study limitations

The experience of end-users of the portal may be affected by loss of smartphones or internet

bundles. Application builds may be unstable on various operating system (OS) versions despite

round the clock efforts to identify and mitigate these hurdles. Network and power outages may

limit access to the portal as well as integration of portal and EMR. These challenges might result

in lower-than-anticipated levels of patient activation from the intervention.

Discussion and Implications

To our knowledge, this is the first study of its kind in Kenya to explore the utility of a smart

phone-based application on patient activation among AYP living with HIV. By engaging this

tech-savvy sub-population that has been shown to have unique needs as equal partners in their

wellness journey through myCareHub®, the study will provide a blue-print that could be

applicable to other diseases and sub-populations, more so as features of the intervention itself

such as quality, fidelity and usability will be documented.

List of References

1.   UNICEF. HIV and AIDS. Protecting children and adolescents from HIV and AIDS and providing care. 2021.

2.   Bekker LG, Hosek S. HIV and adolescents: focus on young key populations: J Int AIDS Soc. 2015 Feb 26;18(2Suppl 1). doi: 10.7448/IAS.18.2.20076. eCollection 2015.

3.   UNAIDS. AIDSinfo global data on HIV epidemiology and response. 2020.

4.   Kemp S. Digital 2021 Kenya2021 14th September 2023. Available from: https://datareportal.com/reports/digital-2021-kenya?rq=kenya.

5.   Nations U. YouthStats: Information and communication technology. . 2022.

6.   Jongbloed K, Parmar S, van der Kop M, Spittal PM, Lester RT. Recent Evidence for Emerging Digital Technologies to Support Global HIV Engagement in Care. Curr HIV/AIDS Rep. 2015;12(4):451-61.

7.   Otte-Trojel T, de Bont A, Rundall TG, van de Klundert J. How outcomes are achieved through patient portals: a realist review. Journal of the American Medical Informatics Association : JAMIA. 2014;21(4):751-7.

8.   West R, Michie S. A brief introduction to the COM-B Model of behaviour and the PRIME Theory of motivation. Qeios. 2020.

9.   WHO. Monitoring and evaluating digital health interventions: a practical guide to conducting research and assessment. Geneva2016.

10.   Marshall R, Beach MC, Saha S, Mori T, Loveless MO, Hibbard JH, et al. Patient activation and improved outcomes in HIV-infected patients. J Gen Intern Med. 2013;28(5):668-74.

11.   Hemming K, Kasza J, Hooper R, Forbes A, Taljaard M. A tutorial on sample size calculation for multiple-period cluster randomized parallel, cross-over and stepped-wedge trials using the Shiny CRT Calculator. Int J Epidemiol. 2020;49(3):979-95.